Stem Cells Derived from Amniotic Fluid: A Potential Pluripotent-Like Cell Source for Cellular Therapy?

Ramasamy, Thamil Selvee; Velaithan, Vithya; Yeow, Yelena; Sarkar, Fazlul H.

doi:10.2174/1574888x13666180115093800

Cited by 12 publications

(10 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As well as stem/stromal cells derived from placenta (Silini and Parolini, 2018), amniotic fluid (Ramasamy et al, 2018), and Wharton's jelly (Joerger-Messerli et al, 2016), MSCs from endometrial tissue can be easily expanded using standardized protocols, and without ethical concerns. This aspect is an important issue, since the simplicity of isolation protocols by non-invasive procedures and the robust expansion capacity of stem cells are crucial for a successful clinical translation of adult stem cells (Bunpetch et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Unraveling the Molecular Signature of Extracellular Vesicles From Endometrial-Derived Mesenchymal Stem Cells: Potential Modulatory Effects and Therapeutic Applications

Marinaro

Gómez-Serrano

Jorge

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Unraveling the Molecular Signature of Extracellular Vesicles From Endometrial-Derived Mesenchymal Stem Cells: Potential Modulatory Effects and Therapeutic Applications

Marinaro

Gómez-Serrano

Jorge

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

“…More recently, amniotic membranes have been investigated as a possible source of stem/progenitor cells for therapeutic applications. In particular, amniotic epithelial cells (AEC) and amniotic fluid mesenchymal stem cells (AFMSC) can be obtained without any ethical limitation [ 16 , 19 ]. Moreover, recently, AECs and AFMSC were both used in preclinical settings of sinus lift [ 20 , 21 ] to evaluate if they could represent an alternative source of progenitor/stem cells for cell therapies in dentistry.…”

Section: Introductionmentioning

confidence: 99%

Biphasic Calcium Phosphate Biomaterials: Stem Cell-Derived Osteoinduction or In Vivo Osteoconduction? Novel Insights in Maxillary Sinus Augmentation by Advanced Imaging

et al. 2021

View full text Add to dashboard Cite

Maxillary sinus augmentation is often necessary prior to implantology procedure, in particular in cases of atrophic posterior maxilla. In this context, bone substitute biomaterials made of biphasic calcium phosphates, produced by three-dimensional additive manufacturing were shown to be highly biocompatible with an efficient osteoconductivity, especially when combined with cell-based tissue engineering. Thus, in the present research, osteoinduction and osteoconduction properties of biphasic calcium-phosphate constructs made by direct rapid prototyping and engineered with ovine-derived amniotic epithelial cells or amniotic fluid cells were evaluated. More in details, this preclinical study was performed using adult sheep targeted to receive scaffold alone (CTR), oAFSMC, or oAEC engineered constructs. The grafted sinuses were explanted at 90 days and a cross-linked experimental approach based on Synchrotron Radiation microCT and histology analysis was performed on the complete set of samples. The study, performed taking into account the distance from native surrounding bone, demonstrated that no significant differences occurred in bone regeneration between oAEC-, oAFMSC-cultured, and Ctr samples and that there was a predominant action of the osteoconduction versus the stem cells osteo-induction. Indeed, it was proven that the newly formed bone amount and distribution decreased from the side of contact scaffold/native bone toward the bulk of the scaffold itself, with almost constant values of morphometric descriptors in volumes more than 1 mm from the border.

show abstract

“…They have also been demonstrated to have a greater hepatogenic and neural differentiation potential than BM-MSC (13, 14). In addition, AF-MSC are immunologically privileged stem cells with higher immunomodulatory characteristics than BM-MSC and they can be used for translational purpose under allogenic conditions (15, 16). Thus overall AF-MSC may be a more suitable source than BM-MSC for regenerative therapies.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Cardiomyogenic Potency of Human Amniotic Fluid and Bone Marrow Mesenchymal Stem Cells

Jain

Minocha

Tripathy

et al. 2019

IJSC

View full text Add to dashboard Cite

Background and ObjectivesMost studies in cardiac regeneration have explored bone marrow mesenchymal stem cells (BM-MSC) with variable therapeutic effects. Amniotic fluid MSC (AF-MSC) having extended self-renewal and multi-potent properties may be superior to bone marrow MSC (BM-MSC). However, a comparison of their cardiomyogenic potency has not been studied yet.MethodsThe 5-azacytidine (5-aza) treated AF-MSC and BM-MSC were evaluated for the expression of GATA-4, Nkx2.5 and ISL-1 transcripts and proteins by quantitative RT-PCR and Western blotting, respectively as well as for the expression of cardiomyogenic differentiation markers cardiac troponin-T (cTNT), beta myosin heavy chain (βMHC) and alpha sarcomeric actinin (ASA) by immunocytochemistry.ResultsThe AF-MSC as compared to BM-MSC had significantly higher expression of GATA-4 (183.06±29.85 vs. 9.80±0.05; p<0.01), Nkx2.5 (8.3±1.4 vs. 1.82±0.32; p<0.05), and ISL-1 (39.59±4.05 vs. 4.36±0.39; p<0.01) genes as well as GATA-4 (2.01±0.5 vs. 0.6±0.1; p<0.05), NKx2.5 (1.9±0.14 vs. 0.8±0.2; p<0.01) and ISL-1 (1.7±0.3 vs. 0.9±0.1; p<0.05) proteins. The AF-MSC also had significantly elevated expression of cTNT (5.0×104±0.6×104 vs. 3.5 ×104±0.8×104; p<0.01), β-MHC (15.7×104±0.9×104 vs. 8.2×104±0.6×104; p<0.01) and ASA (18.6×104±4.9×104 vs. 13.1×104±3.0×104; p<0.05) than BM-MSC.ConclusionsOur data suggest that AF-MSC have greater cardiomyogenic potency than BM-MSC, and thus may be a better source of MSC for therapeutic applications in cardiac regenerative medicine.

show abstract

Stem Cells Derived from Amniotic Fluid: A Potential Pluripotent-Like Cell Source for Cellular Therapy?

Abstract: In short, this cell source could be an ideal cellular resource for pluripotent cells for potential applications in allogeneic cellular replacement therapies, fetal tissue engineering, pharmaceutical screening, and in disease modelling.

Cited by 12 publications

References 92 publications

Unraveling the Molecular Signature of Extracellular Vesicles From Endometrial-Derived Mesenchymal Stem Cells: Potential Modulatory Effects and Therapeutic Applications

Unraveling the Molecular Signature of Extracellular Vesicles From Endometrial-Derived Mesenchymal Stem Cells: Potential Modulatory Effects and Therapeutic Applications

Biphasic Calcium Phosphate Biomaterials: Stem Cell-Derived Osteoinduction or In Vivo Osteoconduction? Novel Insights in Maxillary Sinus Augmentation by Advanced Imaging

Comparison of the Cardiomyogenic Potency of Human Amniotic Fluid and Bone Marrow Mesenchymal Stem Cells

Contact Info

Product

Resources

About